Department of Pathology, UMMS-Baystate

Administration

759 Chestnut Street
Springfield, MA 01199

Chairs

Ashraf Khan, MD, Department Chair

Division Chiefs

David Gang, MD, Anatomic Pathology
Vandita Johari, MD, Clinical Pathology

Education Programs

Residency

Pathology Residency

Fellowship

Cytopathology

4th Year Electives for Medical Students

Scholarly Activity

Research

Baystate Medical Center Pathology academic per capita productivity outpaces many better-known departments. Baystate Pathology is all-inclusive with both anatomic and clinical pathology, to include molecular pathology, cytogenetics, electron microscopy, and immunohistochemistry. All of our board certified pathologists continue their diagnostic skills, enhanced by their diverse subspecialty qualifications, with state-of-the-art technologies deliver the highest quality diagnostic services available. Our faculty credentials include board certifications Clinical Pathology (15) and Anatomic Pathology (19) and subspecialty board certification in:

Dermatopathology
Neuropathology
Cytopathology
Pediatric & Perinatal Pathology
Hematopathology
Transfusion Medicine
Clinical Chemistry
Clinical Microbiology
Toxicology
Clinical Genetics
Clinical Cytogenetics
Molecular Genetics

Our faculty's average age is 10 years younger than the average US pathologist, and they take pride in being aggressive and entrepreneurial. They have trained at world-class institutions, such as Harvard, Yale, Johns Hopkins, Mayo Clinic, Duke, Stanford, and the University of Pennsylvania, and share a commitment to our academic mission, while applying cutting-edge diagnostic technology and clinical care for the benefit of both the patients and physicians of Western Massachusetts.

Publications

View recent Department of Pathology publications in the Scholarly Commons database.

Faculty

Our faculty have primary academic appointments at UMass Medical School-Baystate. View our Pathology faculty profiles on the UMass Medical School website.

Chester Andrzejewski Jr., Ph.D., M.D.
Q. Jackie Cao, M.D., Ph.D.
Lisa L. Cole, M.D.
Giovanna M. Crisi, M.D., Ph.D.
Wayne H. Duke, M.D.
Roxanne R. Florence, M.D.
Katya Ford, M.D.
Jonathan Keen Freeman, M.D.
David L. Gang, M.D.
Jean Marie Henneberry, M.D.
John P. Hunt, M.D.
Rahul Jawale, M.D.
Vandita P. Johari, M.D.
Rukmini Modem Kashikar, M.D.
Olga Krasnozhen-Ratush, M.D.
Paula M. LaPolice, C.T.
Franklin Robert Moore, Ph.D., M.D.
James D. Mueller, M.D.
Christopher N. Otis, M.D.
Lanu Stoddart, M.D.

Highlighting Faculty Achievements

Timothy Mader, MD

Congratulations to Dr. Timothy Mader on receiving a two-year, $222,000 grant from the National Heart, Lung, and Blood Institute at the National Institutes of Health (NIH).

More highlights

Related Clinical Trials

DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial

The purpose of this research study is to compare any good and bad effects of giving ipilimumab, nivolumab, and GM-CSF (Sargramostim) at the same time compared to just ipilimumab and nivolumab together. We would also like to find out what effects, good and bad, that this combination of drugs may have on your cancer.

Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

This randomized phase II trial studies how well ipilimumab with or without bevacizumab works in treating patients with stage III-IV melanoma that cannot be removed by surgery. Immunotherapy with monoclonal antibodies, such as ipilimumab and bevacizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery

A phase II trial of chemotherapeutic agents in patients with diffuse large B-Cell lymphoma

The purpose of this study is to find out what effects, good and/or bad, the addition of lenalidomide to standard chemotherapy (RCHOP)

Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

The purpose of this study is to compare the effects, good and/or bad, of two different therapies that include combinations of the drugs rituximab, fludarabine, cyclophosphamide and ibrutinib.

A phase III trial to combine the effects of a group of medications with another combination in patients with newly diagnosed Symptomatic Multiple Myeloma

This randomized phase III trial studies lenalidomide, dexamethasone, and bortezomib to see how well it works compared to dexamethasone and lenalidomide alone in treating patients with previously untreated multiple myeloma. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the cancer. It is not yet known whether lenalidomide and dexamethasone is more effective with or without bortezomib in treating multiple myeloma.

A Randomized Phase Iii Study Of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone In Untreated Older Patients (≥ 65 Years Of Age) With Chronic Lymphocytic Leukemia (CLL)

The purpose of this study is to compare the effects, good and/or bad, of the drug ibrutinib, either alone or in combination with the drug rituximab, with the standard treatment for this disease.